Pelthos Therapeutics Inc. (PTHS) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 10.91M | 9.39M | 7.41M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 3.17M | 2.89M | 3.38M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | 29.09% | 30.77% | 45.69% | - | - | - | - | - | - | - |
| Gross Profit | 7.73M | 6.5M | 4.02M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | 70.91% | 69.23% | 54.31% | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 20.82M | 18.5M | 19.38M | 3.23M | 1.83M | 1.83M | 2.05M | 1.76M | 1.93M | 3.88M |
| OpEx % of Revenue | 190.91% | 197.07% | 261.73% | - | - | - | - | - | - | - |
| Selling, General & Admin | 20.64M | 18.13M | 19.24M | 2.72M | 1.64M | 1.54M | 1.63M | 1.75M | 1.47M | 1.58M |
| SG&A % of Revenue | 189.21% | 193.09% | 259.78% | - | - | - | - | - | - | - |
| Research & Development | 186K | 374K | 145K | 514.81K | 194.3K | 285.24K | 414.64K | 12.96K | 466.61K | 2.29M |
| R&D % of Revenue | 1.71% | 3.98% | 1.96% | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -13.09M | -12M | -15.36M | -3.23M | -1.83M | -1.83M | -2.05M | -1.76M | -1.93M | -3.88M |
| Operating Margin % | -120.01% | -127.84% | -207.43% | - | - | - | - | - | - | - |
| Operating Income Growth % | -613.64% | -557.68% | -649.98% | -83.12% | 5.17% | 52.95% | - | - | - | - |
| EBITDA | -11.52M | -10.79M | -14.22M | -3.23M | -1.83M | -1.82M | -1.66M | -1.76M | -1.93M | -3.88M |
| EBITDA Margin % | -105.61% | -114.88% | -192.01% | - | - | - | - | - | - | - |
| EBITDA Growth % | -528.03% | -493.04% | -758.88% | -83.49% | 5.17% | 53.11% | - | - | - | - |
| D&A (Non-Cash Add-back) | 1.57M | 1.22M | 1.14M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | -13.09M | -12M | -15.36M | -3.23M | -1.83M | -1.82M | -1.66M | -1.76M | -1.93M | -3.88M |
| Net Interest Income | -2.35M | -1.31M | -1.34M | -218.52K | -133.63K | -107.97K | -39.02K | -11.06K | -628.35K | -160.34K |
| Interest Income | 0 | 0 | 5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 2.35M | 1.31M | 1.35M | 218.52K | 133.63K | 107.97K | 39.02K | 11.06K | 628.35K | 160.34K |
| Other Income/Expense | 2.85M | -16.58M | -1.34M | -218.52K | -133.63K | -101.69K | 353.68K | -7.53K | -628.35K | -160.34K |
| Pretax Income | -10.24M | -28.59M | -16.7M | -3.45M | -1.97M | -1.93M | -1.69M | -1.77M | -2.56M | -4.04M |
| Pretax Margin % | -93.87% | -304.46% | -225.53% | - | - | - | - | - | - | - |
| Income Tax | 0 | -6.92M | -465K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 24.21% | 2.78% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -10.24M | -21.66M | -16.24M | -3.45M | -1.97M | -1.93M | -1.69M | -1.77M | -2.56M | -4.04M |
| Net Margin % | -93.87% | -230.74% | -219.25% | - | - | - | - | - | - | - |
| Net Income Growth % | -420.33% | -1024.39% | -858.19% | -94.68% | 23.21% | 52.3% | - | - | - | - |
| Net Income (Continuing) | -10.24M | -21.66M | -16.24M | -3.45M | -1.97M | -1.93M | -1.69M | -1.77M | -2.56M | -4.04M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.09 | -6.87 | -25.35 | -5.38 | -3.20 | -3.23 | -2.90 | -3.07 | -5.50 | -6.87 |
| EPS Growth % | 3.44% | -112.69% | -774.14% | -75.24% | 41.82% | 52.98% | - | - | - | - |
| EPS (Basic) | -3.09 | -6.87 | -25.35 | -5.38 | -3.20 | -3.23 | -2.90 | -3.07 | -5.50 | -6.87 |
| Diluted Shares Outstanding | 3.31M | 3.15M | 640.52K | 640.52K | 612.79K | 596.01K | 579.23K | 577.37K | 469.1K | 587.78K |
| Basic Shares Outstanding | 3.31M | 3.15M | 640.52K | 640.52K | 612.79K | 596.01K | 579.23K | 577.37K | 469.1K | 587.78K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |